TY - JOUR
T1 - Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
AU - Pradhan, Monika
AU - Chocry, Mathieu
AU - Gibbons, Don L.
AU - Sepesi, Boris
AU - Cascone, Tina
N1 - Funding Information:
Funding: This work was partially supported by the NIH/ NCI P30 CA016672 Cancer Center Support Grant (CCSG), Lung SPORE grant 5 P50 CA070907, the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) Career Development Award 2018, the generous philanthropic contributions to the University of Texas MD Anderson Cancer Center Lung Cancer Moon Shot Program, the University of Texas MD Anderson Cancer Center Khalifa Scholars Award (from Khalifa Bin Zayed Al Nahyan Foundation), the University of Texas MD Anderson Cancer Center Physician Scientist Program, the T.J. Martell Foundation, and the Bob Mayberry Foundation.
Funding Information:
ICMJE uniform disclosure form (available at http:// dx.doi.org/10.21037/tlcr-20-573). The series “Multimodal management of locally advanced N2 non-small cell lung cancer” was commissioned by the editorial office without any funding or sponsorship. DLG has received consulting fee from Astellas and research funding from AstraZeneca, Janssen R&D, Takeda, Ribon Therapeutics, Sanofi, Astellas and has participated in advisory boards for AstraZeneca and Sanofi. BS reports consulting fees from Bristol-Myers Squibb. TC reports speaker’s fees from Society for Immunotherapy of Cancer (SITC) and Bristol-Myers Squibb, consulting fees from MedImmune/AstraZeneca and Bristol-Myers Squibb, and advisory role fees from EMD Serono and Bristol-Myers Squibb and clinical research funding to MD Anderson Cancer Center from Boehringer Ingelheim, MedImmune/AstraZeneca , EMD Serono and Bristol-Myers Squibb. The authors have no other conflicts of interest to declare.
Publisher Copyright:
© 2021 Translational Lung Cancer Research.
PY - 2021/1
Y1 - 2021/1
N2 - The advent of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of patients with locally advanced unresectable and metastatic non-small cell lung cancer (NSCLC). Now, ICIs are undergoing evaluation as neoadjuvant therapy in patients with early-stage, resectable NSCLC using candidate surrogate endpoints of clinical efficacy, i.e., major pathologic response (MPR, ≤10% viable tumor cells in resected tumors). The initial results from early, small-scale trials are encouraging; however, they also reveal that a substantial number of patients with operable disease may not benefit from neoadjuvant ICIs. Consequently, much investigative effort is currently directed toward identifying mechanisms of resistance to ICI therapy in resectable NSCLC. There is also an urgent need for biomarkers that could be used to guide the clinical decision-making process and maximize the clinical benefit of ICIs in patients with early-stage, resectable NSCLC. Here, we summarize the initial results from the trials of neoadjuvant ICIs in patients with early-stage and locally advanced operable NSCLC and review the findings of studies investigating emerging biomarkers associated with those trials.
AB - The advent of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of patients with locally advanced unresectable and metastatic non-small cell lung cancer (NSCLC). Now, ICIs are undergoing evaluation as neoadjuvant therapy in patients with early-stage, resectable NSCLC using candidate surrogate endpoints of clinical efficacy, i.e., major pathologic response (MPR, ≤10% viable tumor cells in resected tumors). The initial results from early, small-scale trials are encouraging; however, they also reveal that a substantial number of patients with operable disease may not benefit from neoadjuvant ICIs. Consequently, much investigative effort is currently directed toward identifying mechanisms of resistance to ICI therapy in resectable NSCLC. There is also an urgent need for biomarkers that could be used to guide the clinical decision-making process and maximize the clinical benefit of ICIs in patients with early-stage, resectable NSCLC. Here, we summarize the initial results from the trials of neoadjuvant ICIs in patients with early-stage and locally advanced operable NSCLC and review the findings of studies investigating emerging biomarkers associated with those trials.
KW - Biomarkers
KW - Early-stage non-small cell lung cancer (early-stage NSCLC)
KW - Neoadjuvant immune checkpoint inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85100739693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100739693&partnerID=8YFLogxK
U2 - 10.21037/tlcr-20-573
DO - 10.21037/tlcr-20-573
M3 - Review article
C2 - 33569339
AN - SCOPUS:85100739693
SN - 2218-6751
VL - 10
SP - 590
EP - 606
JO - Translational Lung Cancer Research
JF - Translational Lung Cancer Research
IS - 1
ER -